Lack of Association between Intact/Deletion Polymorphisms of the APOBEC3B Gene and HIV-1 Risk
暂无分享,去创建一个
T. Naoe | W. Sugiura | Y. Koyanagi | Kei Sato | A. Takaori-Kondo | T. Shirasaka | H. Ode | Y. Yokomaku | Y. Iwatani | Junji Imamura | K. Matsuoka | Dai Watanabe | Taisuke Izumi | M. Imahashi | M. Utsumi | T. Masaoka | S. Ichikawa | Noriyo Kaneko | Mayumi Imahashi | Takashi Masaoka
[1] Wei Zheng,et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. , 2013, Carcinogenesis.
[2] N. A. Temiz,et al. Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.
[3] Jason B. Nikas,et al. APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.
[4] N. Kadowaki,et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells , 2012, Scientific Reports.
[5] V. Pathak,et al. APOBEC3G Restricts HIV-1 to a Greater Extent than APOBEC3F and APOBEC3DE in Human Primary CD4+ T Cells and Macrophages , 2012, Journal of Virology.
[6] W. Sugiura,et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding , 2012, Nature Structural &Molecular Biology.
[7] R. D’Aquila,et al. APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. , 2012, Virology.
[8] V. Simon,et al. APOBEC3A, APOBEC3B, and APOBEC3H Haplotype 2 Restrict Human T-Lymphotropic Virus Type 1 , 2012, Journal of Virology.
[9] Lela Lackey,et al. Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1 , 2011, Journal of Virology.
[10] V. Pathak,et al. The Role of Amino-Terminal Sequences in Cellular Localization and Antiviral Activity of APOBEC3B , 2011, Journal of Virology.
[11] V. Pathak,et al. Identification of Specific Determinants of Human APOBEC3F, APOBEC3C, and APOBEC3DE and African Green Monkey APOBEC3F That Interact with HIV-1 Vif , 2010, Journal of Virology.
[12] W. Sugiura,et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. , 2010, Antiviral research.
[13] T. Nakajima,et al. No evidence of an association between the APOBEC3B deletion polymorphism and susceptibility to HIV infection and AIDS in Japanese and Indian populations. , 2010, The Journal of infectious diseases.
[14] Ariana Harari,et al. Moderate Influence of Human APOBEC3F on HIV-1 Replication in Primary Lymphocytes , 2010, Journal of Virology.
[15] W. Brown,et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction , 2010, Nucleic acids research.
[16] John S. Albin,et al. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics , 2010, Expert Reviews in Molecular Medicine.
[17] Yusuke Nakamura,et al. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.
[18] Y. Xiong,et al. A Single Amino Acid Difference in Human APOBEC3H Variants Determines HIV-1 Vif Sensitivity , 2009, Journal of Virology.
[19] M. Emerman,et al. The Range of Human APOBEC3H Sensitivity to Lentiviral Vif Proteins , 2009, Journal of Virology.
[20] J. Goedert,et al. APOBEC3B deletion and risk of HIV-1 acquisition. , 2009, The Journal of infectious diseases.
[21] M. Malim,et al. Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets , 2009, Journal of Virology.
[22] R. D’Aquila,et al. Differences in APOBEC3G Expression in CD4+ T Helper Lymphocyte Subtypes Modulate HIV-1 Infectivity , 2009, PLoS pathogens.
[23] M. Malim,et al. APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts , 2008, PLoS pathogens.
[24] V. Pathak,et al. Distinct Domains within APOBEC3G and APOBEC3F Interact with Separate Regions of Human Immunodeficiency Virus Type 1 Vif , 2008, Journal of Virology.
[25] S. O’Brien,et al. Guidelines for Naming Nonprimate APOBEC3 Genes and Proteins , 2008, Journal of Virology.
[26] J. Sankalé,et al. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. , 2008, The Journal of infectious diseases.
[27] K. Strebel,et al. HIV-1 Vif, APOBEC, and Intrinsic Immunity , 2008, Retrovirology.
[28] B. Cullen,et al. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. , 2008, RNA.
[29] J. Greeve,et al. Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. , 2007, The Journal of general virology.
[30] A. Gronenborn,et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G , 2007, Nucleic acids research.
[31] E. Eichler,et al. Population Stratification of a Common APOBEC Gene Deletion Polymorphism , 2007, PLoS genetics.
[32] L. Lopalco,et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. , 2007, The Journal of infectious diseases.
[33] P. Spearman,et al. APOBEC3G Multimers Are Recruited to the Plasma Membrane for Packaging into Human Immunodeficiency Virus Type 1 Virus-Like Particles in an RNA-Dependent Process Requiring the NC Basic Linker , 2007, Journal of Virology.
[34] M. Stenglein,et al. APOBEC3B and APOBEC3F Inhibit L1 Retrotransposition by a DNA Deamination-independent Mechanism* , 2006, Journal of Biological Chemistry.
[35] H. Takeuchi,et al. Biochemical Activities of Highly Purified, Catalytically Active Human APOBEC3G: Correlation with Antiviral Effect , 2006, Journal of Virology.
[36] T. Rana,et al. Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing Bodies , 2006, PLoS pathogens.
[37] B. Cullen,et al. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. , 2005, Virology.
[38] S. Wain-Hobson,et al. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. , 2005, The Journal of general virology.
[39] S. Heath,et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. , 2005, The Journal of infectious diseases.
[40] R. König,et al. APOBEC3B and APOBEC3C Are Potent Inhibitors of Simian Immunodeficiency Virus Replication* , 2004, Journal of Biological Chemistry.
[41] V. Pathak,et al. Human Apolipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G (APOBEC3G) Is Incorporated into HIV-1 Virions through Interactions with Viral and Nonviral RNAs* , 2004, Journal of Biological Chemistry.
[42] M. Malim,et al. Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins , 2004, Current Biology.
[43] Yunkai Yu,et al. Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.
[44] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[45] Shuhua Xu,et al. Deletion of the APOBEC3B gene strongly impacts susceptibility to falciparum malaria. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[46] Xianghui Yu,et al. Induction of APOBEC 3 G Ubiquitination and Degradation by an HIV-1 Vif-Cul 5-SCF Complex , 2022 .